🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Time for a new look at how to manage LN. The old proteinuric centric approach is not enough. In patients with anti-ds-DNA and proliferative LN, targeting immunological remission (negative anti-ds-DNA and normalization of complement) is the key 🔑! kidney-international.org/article/S0085-…

"Normal" Glomerular Score correlates with outcomes in ANCA-associated Vasculitis with Glomerulonephritis. #MayoClinicKidney fernando fervenza Sanjeev Sethi kireports.org/article/S2468-…

Thanksgiving Eve around the microscope, with the Fellows. Teaching is one of the great joys of life. Happy Thanksgiving everyone. Mayo Clinic Pathology Mayo Clinic Nephrology

Sanjeev Sethi’s Birthday 🎂 Sanjeev Sethi maria jose vargas Congratulations 🎈🎉🎊🍾👏👏👏

Always a joy to teach and have company while signing out my Saturday morning cases. Anila & Gianmarco are among the most sincere & dedicated fellows I have met. Saw 9 cases ranging from ATN, lupus nephritis, IgA, diabetes, interstitial nephritis, membranous & myeloma kidney.

Rare case of CLL associated with membranous nephropathy (MN) MN was PLA2R & THSD7A negative Laser dissection & Mass spec showed antigen HTRA1 (completely unexpected) Treatment of CLL= remission of proteinuria HTRA1- positive MN in a patient with CLL - kireports.org/article/S2468-…

For the 7th straight year, Newsweek has named Mayo Clinic the No. 1 hospital in its "World’s Best Hospitals" rankings. “Mayo Clinic’s dedicated staff make this possible,” says CEO @GFarrugiaMDGianrico Read more: mayocl.in/41ko7OH

Spring at Mayo Mayo Clinic, almost Spring in Rochester 😊

🆕 Case report in The Lancet Infectious Diseases: Exploring parvovirus B19 pathogenesis and therapy among kidney transplant recipients. A 34-year-old male recipient of an ABO-incompatible living donor kidney transplant who was repeatedly hospitalised for anaemia: hubs.li/Q03cvfHZ0

The Mayo MGRS Prediction Tool calculates the risk of finding monoclonal gammopathy of renal significance in a kidney biopsy in patients with monoclonal gammopathy! Proud of my friend maria jose vargas and the Mayo GN group! kidney-international.org/article/S0085-…

Many people tried to prevent publication of this data. Puts to rest claims that we don’t have hard-end points in MN treated with RTX! Long-term Outcome of Adult Patients with Membranous Nephropathy treated with Rituximab. - Kidney International Reports kireports.org/article/S2468-…

Mayo MGRS Prediction Tool calculator mdevans.shinyapps.io/mgrs_app/

Gian Marco- It was wonderful having you train with us. Seven months went by quickly-you were at every renal pathology sign out with me. You never missed my weekend sign out taking every opportunity to learn. Wish you all the best for your future. Safe travels to Bologna 🇮🇹

Our Mayo Clinic Nephrology ‘s Dr. Fernando C. Fervenza presented: “Lupus Nephritis: Redefining Treatment Goals” fernando fervenza Followed by thought-provoking discussions on lupus nephritis- Dr. Ayoub and Dr.Fervenza The 7th International Renal Meeting in Sardinia 🇮🇹 Andrea Angioi, MD, FASN

Long-term Outcome of Adult Patients with Membranous Nephropathy treated with Rituximab fernando fervenza maria jose vargas Ilario Russo, MD Sanjeev Sethi Ladan Zand kireports.org/article/S2468-…

Long-term Outcome of Adult Patients with Membranous Nephropathy treated with Rituximab. Sanjeev Sethi Ladan Zand fernando fervenza #MayoClinicKidney kireports.org/article/S2468-…

Clinical trial at our Mayo Clinic Nephrology: Evaluating daratumumab for treatment of PGNMID (Proliferative Glomerulonephritis with Monoclonal Immune Deposits). A novel approach to a rare glomerular disease. fernando fervenza Ladan Zand Learn More🔗 mayo.edu/research/clini…

Mayo Clinic Laboratories' new mass spectrometry assay requires just one small tissue sample to identify 13 antigens known to cause membranous nephropathy. Learn more about this one-stop test. Sanjeev Sethi bit.ly/4k1loks